Failed I-PRESERVE trial highlights need for new approach in heart failure
This article was originally published in Scrip
New approaches are needed to treat heart failure in the 50% of patients who have a normal or near normal left ventricular ejection fraction, experts say after the failure of the I-PRESERVE trial ofBristol-Myers Squibb/Sanofi-Aventis's angiotensin II receptor blocker irbesartan (Aprovel).
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.